Stock Financial Ratios and Split History

XLRN / Acceleron Pharma Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,984.81
Enterprise Value ($M)1,834.25
Book Value ($M)365.22
Book Value / Share8.04
Price / Book5.43
NCAV ($M)261.28
NCAV / Share5.75
Price / NCAV7.34
Income Statement (mra) ($M)
Net Income-108.45
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Quick Ratio17.03
Current Ratio17.03
Share Statistics
Common Shares Outstanding45,419,061
Common Stock Shares Outstanding45,261,175
Preferred Stock Shares Outstanding0
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.30
Return on Assets (ROA)-0.44
Return on Equity (ROE)-0.48
Identifiers and Descriptors
Central Index Key (CIK)1280600
Industry Groups
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech)
Related CUSIPS
000434H10 00434H958 00434H908

Split History

Stock splits are used by Acceleron Pharma Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related News Stories

Celgene Vs. Biogen: Both Are A Steal, But Which One Is Better?

2018-03-05 seekingalpha
Finally, we discuss which of the two would make a better addition to a well-diversified biotech portfolio. (445-0)

Biotech Forum Daily Digest For March 1st

2018-03-01 seekingalpha
Yesterday closed out the books on February, which was a negative month for the biotech sector and the overall market. (218-2)

Acceleron Pharma's (XLRN) CEO Habib Dable on Q4 2017 Results - Earnings Call Transcript

2018-02-28 seekingalpha
Acceleron Pharma Inc. (NASDAQ:XLRN) Q4 2017 Results Earnings Conference Call February 27, 2018 5:00 PM ET (69-0)

Acceleron Pharma Inc. 2017 Q4 - Results - Earnings Call Slides

2018-02-28 seekingalpha
The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2017 Q4 earnings call. (2-0)

Celgene In 2018: A Look At The Long Thesis

2018-02-13 seekingalpha
The company is posturing for a transition to a time and place without patent protections on Revlimid. (61-0)

CUSIP: 00434H108